General Discussions

Expert Discusses Recent CLL Approval

By Suman Kambhampati, MD
PUBLISHED WEDNESDAY, DECEMBER 31, 1969


Suman Kambhampati, MD, the co-director of blood cancer research at Sarah Cannon Cancer Institute at HCA Midwest Health, discusses the recent FDA approval of ibrutinib (Imbruvica) plus obinutuzumab (Gazyva) for the frontline treatment of patients with chronic lymphocytic leukemia (CLL).

The approval was based on the phase III iLLUMINATE trial, which showed that ibrutinib plus obinutuzumab was the first non-chemotherapy combination that was extremely effective in treating nearly all subtypes of patients with CLL. The combination elicited a longer progression-free survival (PFS), nearly a 100% response rate, and better complete responses (CR) than treatment with ibrutinib alone, making it an extremely exciting treatment option for these patients.
Start a discussion
You must log in to use this feature, please click here to login.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.